Myriad Genetics (MYGN) Guidance Looks Conservative, Says Goldman Sachs
Tweet Send to a Friend
Goldman Sachs maintained a Neutral rating on Myriad Genetics (NASDAQ: MYGN) and lowered its price target to $31.00 (from $32.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
